Samuel D. Waksal, PhD
Dr. Waksal is Chairman and Founder of Kadmon Corporation. Dr. Waksal is the founder and former President and CEO of ImClone Systems (sold to Eli Lilly & Co. in 2008 for $6.5 billion), developer of Erbitux®, one of the top-selling cancer drugs in the world.
Dr. Waksal spent the first half of his career in academic medicine. He was a professor of pathology and the director of the Division of Immunotherapy at the Mount Sinai School of Medicine in New York. He also served as visiting investigator at the National Cancer Institute, Immunology Branch, a research associate in the Department of Genetics at Stanford University Medical School, an assistant professor at Tufts University School of Medicine and a senior scientist at the Tufts Cancer Research Center.
Dr. Waksal was a scholar of the Leukemia Society of America, and has been a visiting professor at the Pasteur Institute in France and the Weizmann Institute of Science in Israel. He was a member of the Board of Advisors of Rockefeller University and for many years was the Chairman of the New York State Council for the Humanities. Dr. Waksal has served as a board member for several public and private companies, including Medicis Pharmaceuticals, Antigenics and ValiGen.